Vaccinex Reports Clinical Benefit In Interim Analyses From Two Phase 2 Studies Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer’s Annual Meeting
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the 38th Annual Meeting of the Society for Immunotherapy of